Status and phase
Conditions
Treatments
About
This is a double-blinded, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics, and antiviral activity in both healthy volunteers and volunteers with chronic hepatitis B virus infection. Healthy volunteers will be administered either a single oral dose or multiple oral doses of ATI-2173 and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug. Volunteers with a diagnosis of chronic hepatitis B virus infection will be administered multiple oral doses of ATI-2173 and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All subjects:
Provision of signed and dated informed consent form (ICF)
Stated willingness to comply with all study procedures and availability for the duration of the study
If female, meets 1 of the following criteria:
Is of childbearing potential and agrees to use an accepted contraceptive method. Acceptable method of contraception include:
Male partner has had a vasectomy less than 6 months prior to dosing, and agrees to use an additional acceptable contraceptive method from the first study drug administration through to at least 30 days after the last dose of the study drug or until completion of the study, whichever is longer Or
Is of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e. at least 1 year without menses without an alternative medical condition prior to the first study drug administration and follicle-stimulating hormone levels ≥ 40 mIU/mL at screening)
If male, meets 1 of the following criteria:
Is able to procreate and agrees to use 1 of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration. An acceptable method of contraception includes 1 of the following:
Is unable to procreate; defined as surgically sterile (i.e. has undergone a vasectomy at least 180 days prior to the first study drug administration)
Light-, non- or ex-smoker (A light-smoker is defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration. An ex smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)
Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without clinical significance, as determined by an investigator
Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an investigator
Healthy subjects (Phase 1a):
Male or female, aged at least 18 years but not older than 55 years
Body mass index (BMI) within 18.0 kg/m2 to 32.0 kg/m2, inclusive
HBV-infected subjects (Phase 1b):
Male or female, aged at least 18 years but not older than 65 years
BMI within 18.0 kg/m2 to 35.0 kg/m2, inclusive
Serum HBsAg positive at screening and at least 6 months prior to screening
Serum HBeAg positive and HBV DNA ≥ 20,000 IU/mL, or serum HBeAg negative and HBV DNA ≥ 2,000 IU /mL at screening
ALT and AST <5 times the upper limit of normal (ULN) at screening and prior to the first study drug administration
Exclusion criteria
All subjects:
Female who is lactating at screening
Female who is pregnant according to the pregnancy test at screening or prior to the first study drug administration
History of significant hypersensitivity to clevudine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
Presence of clinically significant muscle disorders, myopathies or other forms of liver disease
Presence of clinically significant ECG abnormalities at the screening visit, as defined by medical judgment
Positive test result for alcohol and/or drugs of abuse at screening or prior to the first drug administration
Any history of tuberculosis
Inclusion in a previous cohort for this clinical study
Intake of an Investigational Product (IP) in the 28 days prior to the first study drug administration
Active illicit drug use including, but not limited to, cocaine, heroin and methamphetamine (the use of cannabinoid is acceptable)
Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
Donation of 500 mL or more of blood in the 56 days prior to the first study drug administration
Healthy subjects (Phase 1a):
Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
Any clinically significant illness in the 28 days prior to the first study drug administration
Presence or history of clinically significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability
Positive screening results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus tests
Use of any prescription drugs including amiodarone (with the exception of hormone replacement therapy) in the 28 days prior to the first study drug administration, that in the opinion of an investigator would put into question the status of the participant as healthy
HBV-infected subjects (Phase 1b):
Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
Use of amiodarone in the 28 days prior to the first study drug administration
Presence or history of clinically significant gastrointestinal or kidney disease, or surgery that may affect drug bioavailability
Cirrhosis of the liver as determined by one of the following:
Medical history or known presence of hepatocellular carcinoma
Previous treatment for hepatitis B virus, including nucleoside therapy
Acute infection or any other clinically significant illness within 14 days of randomization
History of organ transplantation
Uncontrolled hypertension
Positive screening results to HIV Ag/Ab combo, hepatitis C virus or hepatitis D virus tests
Primary purpose
Allocation
Interventional model
Masking
88 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal